Inventiva secures financing of up to €348M to advance the Nativ3 phase 3 MASH study
Akarapong Chairean Inventiva (NASDAQ:IVA) on Monday said that it secured financing of immediately €94.1 million and up to €348 million to fund the completion of the NATiV3 Phase III MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor. The transaction was led by New Enterprise Associates, BVF Partners LP and Samsara BioCapital, with the participation of additional existing and new investors.Source: Press Release
Disclaimer: The views in this article are from the original author and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
